On Wednesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Micron Technology, Inc. (NASDAQ:MU), GOL Linhas Aéreas Inteligentes S.A. (NYSE:GOL), Cytori Therapeutics, Inc. (NASDAQ:CYTX), Illumina Inc. (NASDAQ:ILMN)
Micron Technology, Inc. (NASDAQ:MU), with shares declined -4.97%, closed at $26.57.
GOL Linhas Aéreas Inteligentes S.A. (NYSE:GOL), with shares dropped -4.91%, settled at $2.71.
Cytori Therapeutics, Inc. (NASDAQ:CYTX), with shares dipped -4.03%, and closed at $1.19.
Illumina Inc. (NASDAQ:ILMN), plummeted -4%, and closed at $183.28.
Latest NEWS regarding these Stocks are depicted underneath:
Micron Technology, Inc. (NASDAQ:MU)
On Wednesday, Micron Technology, Inc. (MU)’s coverage has been initiated by MKM Partners with a “neutral” rating.
The analyst firm set a price target of $33 for the chipmaker. MKM Partners anticipates Micron to report earnings of $3.07 a share for 2015. The firm set its 2016 and 2017 EPS estimates for the corporation at $3.58 and $3.78 a share, respectively.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The corporation manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems. It operates in four segments: Compute and Networking Business Unit, Mobile Business Unit, Storage Business Unit, and Embedded Business Unit.
GOL Linhas Aéreas Inteligentes S.A. (NYSE:GOL)
GOL Linhas Aéreas Inteligentes S.A. (GOL), declared Material Fact on Monday. The largest low-cost and best-fare airline corporation in Latin America, in compliance with article 157, §4 of Law no. 6,404/76 and CVM Instruction no. 358/2002, in addition to the Material Fact dated January 21, 2015, hereby declares the approval by its shareholders, on the Special General Meeting held on this date, of the proposal to improve the Corporation’s capitalization capacity, counting the ordinary stock split and amendments to the Bylaws to improve corporate governance.
Shareholders representing 81.70% of the capital stock of the Corporation attended or were represented at the meeting, counting holders of 100% of ordinary shares and 62.79% of preferred shares. Shareholders representing 51.51% of the outstanding preferred shares (not including the controlling shareholder and administration of the Corporation) attended or were represented at the meeting and voted in favor of the Operation.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. It operates in two segments, Flight Transportation and Smiles Loyalty Program.
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (CYTX), declared that it will formally launch and showcase its new Celase® GMP enzyme at the 2015 International Society for Cellular Therapy (ISCT) annual meeting on May 27th to 30th in Las Vegas. This will mark the first time that Cytori has made Celase® GMP accessible for purchase as a standalone product.
Celase® is a proprietary enzyme blend that was designed specifically to optimize Cytori’s automated adipose tissue dissociation process. Celase® is produced using avian and mammalian tissue-free raw materials, aseptic processes and sterile filtration under cGMP guidelines.
Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications. Celase® has been approved by the U.S. FDA for use in clinical trials evaluating Cytori Cell Therapy™ in patients with chronic heart failure, osteoarthritis of the knee and hand manifestations of scleroderma.
“Cytori’s new Celase® GMP product will provide researchers with superior and unparalleled convenience in their lab, clarity in their approach, and confidence in their results,” said Russ Havranek, Director of Global Marketing and Sales at Cytori Therapeutics.
Cytori Therapeutics, Inc., a biotechnology corporation, develops cell therapeutics for specific diseases and medical conditions. The corporation primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
Illumina Inc. (NASDAQ:ILMN)
Formerly on March 10, Illumina Inc. (ILMN), declared it has formed a partnership with Merck Serono, the biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic. In addition to separate collaborations with AstraZeneca, Janssen Biotech, Inc., and Sanofi, Illumina and Merck Serono will work to create a universal test system for clinical trials of targeted cancer therapies, with the aim of a more comprehensive tool for precision medicine.
Illumina is working with Merck Serono to develop assays that detect and measure multiple variants simultaneously to support clinical trials. The partnership toward the universal cancer test will comprise test development, worldwide regulatory approvals, and global commercialization. In parallel, Illumina continues to collaborate with the key thought leaders of the Actionable Genome Consortium to set standards for NGS-based assays in routine clinical oncology practice, in addition to define regulatory frameworks to enable this new testing paradigm.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The corporations products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
